Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | FABP1 | P07148 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21395913 | 0.94 | FABP1 (0.38) | PDE4DPDE4APDE4CPDE4BABCG2 | |
| SCHEMBL21396160 | 0.90 | FABP1 (0.40) | PDE4DPDE4APDE4CPDE4BABCG2 | |
| SCHEMBL21395915 | 0.88 | FABP1 (0.38) | PDE4DPDE4APDE4CABCG2FABP1 | |
| SCHEMBL21395910 | 0.87 | PDE4D (0.40) | PDE4DPDE4APDE4CPDE4BADORA2A | |
| SCHEMBL15248219 | 0.82 | KDM4E (0.44) | ADORA2ACLK4ALDH1A3IRAK4MAP4K4 | |
| SCHEMBL16456283 | 0.82 | TDP2 (0.37) | PDE4DPDE4APDE4CPDE4BABCG2 | |
| SCHEMBL21395917 | 0.81 | PARP1 (0.42) | FABP1 | |
| SCHEMBL16558156 | 0.81 | FABP1 (0.41) | PDE4DPDE4APDE4CABCG2FABP1 | |
| SCHEMBL16561058 | 0.81 | FABP1 (0.41) | PDE4DPDE4APDE4CPDE4BABCG2 | |
| SCHEMBL21395955 | 0.81 | CYP1A2 (0.44) | ADORA2AABCG2CLK4ALDH1A3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292169-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292169-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LAGE3, PPOX, SUN2 | PDE4D 3994/4885PDE4A 4260/4885PDE4C 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.